Elanco Q3 revenue $1.14B (+10% YoY); raises FY guidance, net leverage improves

Elanco Animal Health Inc

2025-Q3 EPS reported $0.09 revenue$3,571,000,000

Q3 revenue $1,137M (+10% reported, +9% organic CC); adjusted EPS $0.19 vs $0.13 YoY (+46%).
Adjusted EBITDA $198M (+21%); net leverage ratio improved to 3.7x from 4.3x at FY 2024 end.
Raises FY 2025 revenue guidance to $4,645-4,670M and adjusted EPS to $0.91-0.94 (from $0.85-0.91).
Pet Health revenue $533M (+10%), driven by Credelio Quattro ($100M net sales in <8 months) and Zenrelia.
Refinanced $2.1B Term Loan B, extending maturities through 2032 and reducing interest cost.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.